TABLE OF CONTENTS
1 INTRODUCTION 54
1.1 OBJECTIVES OF THE STUDY 54
1.2 MARKET DEFINITION 54
1.3 OVERVIEW OF THE EUROPE EXOSOME RESEARCH PRODUCTS MARKET 54
1.4 LIMITATIONS 56
1.5 MARKETS COVERED 56
2 MARKET SEGMENTATION 59
2.1 MARKETS COVERED 59
2.2 GEOGRAPHICAL SCOPE 60
2.3 YEARS CONSIDERED FOR THE STUDY 61
2.4 CURRENCY AND PRICING 61
2.5 DBMR TRIPOD DATA VALIDATION MODEL 62
2.6 MULTIVARIATE MODELLING 65
2.7 PRODUCT LIFELINE CURVE 66
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 67
2.9 DBMR MARKET POSITION GRID 68
2.10 MARKET APPLICATION COVERAGE GRID 70
2.11 VENDOR SHARE ANALYSIS 71
2.12 SECONDARY SOURCES 72
2.13 ASSUMPTIONS 72
3 EXECUTIVE SUMMARY 73
4 PREMIUM INSIGHTS 75
4.1 PESTEL ANALYSIS 76
4.2 PORTER'S FIVE FORCES MODEL 77
4.3 SUPPLY CHAIN ANALYSIS 78
4.4 VALUE CHAIN ANALYSIS 79
4.5 BUSINESS STRATEGY EXCELLENCE 80
4.6 CASE STUDIES 81
4.7 STRENGTH OF PRODUCT PORTFOLIO 83
4.8 TECHNOLOGICAL TRENDS 85
4.9 PRICING ANALYSIS 86
5 INDUSTRY INSIGHTS 87
6 EUROPE EXOSOME RESEARCH PRODUCTS MARKET, REGULATIONS 88
7 MARKET OVERVIEW 90
7.1 DRIVERS 92
7.1.1 GROWING PREVALENCE OF CANCER, CHRONIC INFLAMMATION, AUTOIMMUNE DISEASE, LYME DISEASE, AND OTHER CHRONIC DEGENERATIVE DISEASES 92
7.1.2 INCREASING INVESTMENTS IN PHARMACEUTICAL R&D AND LIFE SCIENCES RESEARCH 92
7.1.3 AVAILABILITY OF VARIOUS EXOSOME ISOLATION AND PURIFICATION TECHNIQUES AND PROGRESSING THERAPEUTIC VALUE OF EXOSOME 93
7.2 RESTRAINTS 94
7.2.1 LACK OF GOLD STANDARD PROTOCOLS FOR THE DEVELOPMENT AND PRODUCTION OF EXOSOMES 94
7.2.2 THE SHORTAGE OF SKILLED PROFESSIONALS REQUIRED FOR THE ISOLATION OF EXOSOME 94
7.3 OPPORTUNITIES 95
7.3.1 RISING DEMAND FOR SPECIALIZED TESTING SERVICES AMONG END USERS. 95
7.3.2 INCREASING ADVANCEMENT IN EXOSOME TECHNOLOGY 95
7.3.3 STRATEGIC INITIATIVES BY MARKET PLAYERS 96
7.4 CHALLENGES 97
7.4.1 SIDE EFFECTS ASSOCIATED WITH EXOSOME RESEARCH PRODUCTS 97
7.4.2 LATE APPROVAL ASSOCIATED WITH PRODUCT LAUNCHES 97
8 EUROPE EXOSOME RESEARCH PRODUCTS MARKET, BY PRODUCT 98
8.1 OVERVIEW 99
8.2 CONSUMABLES 102
8.2.1 KITS AND REAGENTS 103
8.2.1.1 EXOSOME BIOMARKER KITS 104
8.2.1.2 EXOSOME ISOLATION KITS 104
8.2.1.3 EXOSOME PURIFICATION KITS 104
8.2.1.4 EXOSOME QUANTITATIVE KITS 104
8.2.1.5 EXOSOME DETECTION KITS 104
8.2.1.6 OTHERS 104
8.2.2 EXOSOME STANDARDS 104
8.2.3 EXOSOME ANTIBODIES 104
8.2.4 CELL LINES 104
8.2.5 IMMUNOPLATES 105
8.2.6 IMMUNOBEADS 105
8.2.7 BIOFLUIDS 105
8.2.8 OTHERS 105
8.3 INSTRUMENTS 105
8.3.1 BENCHTOP 106
8.3.2 STANDALONE 106
9 EUROPE EXOSOME RESEARCH PRODUCTS MARKET, BY INDICATION 107
9.1 OVERVIEW 108
9.2 CANCER 111
9.2.1 LUNG CANCER 112
9.2.2 BREAST CANCER 112
9.2.3 COLORECTAL CANCER 112
9.2.4 PROSTATE CANCER 113
9.2.5 OTHER CANCER 113
9.3 NON-CANCER 113
9.3.1 CARDIOVASCULAR DISEASE 114
9.3.2 NEURODEGENERATIVE DISEASE 114
9.3.3 INFECTIOUS DISEASE 114
9.3.4 OTHERS 114
10 EUROPE EXOSOME RESEARCH PRODUCTS MARKET: BY APPLICATION 115
10.1 OVERVIEW 116
10.2 THERAPEUTICS 119
10.3 CONSUMABLES 120
10.4 INSTRUMENTS 120
10.5 DIAGNOSIS 120
10.6 CONSUMABLES 121
10.7 INSTRUMENTS 121
11 EUROPE EXOSOME RESEARCH PRODUCTS MARKET, BY END USER 122
11.1 OVERVIEW 123
11.2 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANY 126
11.3 CONSUMABLES 127
11.4 INSTRUMENTS 127
11.5 RESEARCH CENTRES 127
11.6 CONSUMABLES 128
11.7 INSTRUMENTS 128
11.8 ACADEMIC INSTITUTES 128
11.9 CONSUMABLES 129
11.10 INSTRUMENTS 129
11.11 CLINICAL TESTING LABORATORY 129
11.12 CONSUMABLES 130
11.13 INSTRUMENTS 130
11.14 HOSPITALS 131
11.15 CONSUMABLES 132
11.16 INSTRUMENTS 132
11.17 OTHERS 132
12 EUROPE EXOSOME RESEARCH PRODUCTS MARKET, BY DISTRIBUTION CHANNEL 133
12.1 OVERVIEW 134
12.2 THIRD PARTY DISTRIBUTORS 137
12.3 DIRECT SALES 137
12.4 ONLINE 138
13 EUROPE EXOSOME RESEARCH PRODUCTS MARKET, BY REGION 139
13.1 EUROPE 140
13.1.1 GERMANY 151
13.1.2 U.K. 157
13.1.3 FRANCE 163
13.1.4 ITALY 169
13.1.5 SPAIN 175
13.1.6 RUSSIA 181
13.1.7 SWITZERLAND 187
13.1.8 NETHERLANDS 193
13.1.9 TURKEY 199
13.1.10 SWEDEN 205
13.1.11 POLAND 211
13.1.12 NORWAY 217
13.1.13 BELGIUM 223
13.1.14 FINLAND 229
13.1.15 DENMARK 235
13.1.16 REST OF EUROPE 241
14 EUROPE EXOSOME RESEARCH PRODUCTS MARKET, COMPANY LANDSCAPE 242
14.1 COMPANY SHARE ANALYSIS: EUROPE 242
15 SWOT ANALYSIS 243
16 COMPANY PROFILE 244
16.1 THERMO FISHER SCIENTIFIC INC. 244
16.1.1 COMPANY SNAPSHOT 244
16.1.2 REVENUE ANALYSIS 244
16.1.3 COMPANY SHARE ANALYSIS 245
16.1.4 PRODUCT PORTFOLIO 245
16.1.5 RECENT DEVELOPMENT 246
16.2 EXODX (ACQUIRED BY BIO-TECHNE) 247
16.2.1 COMPANY SNAPSHOT 247
16.2.2 REVENUE ANALYSIS 247
16.2.3 COMPANY SHARE ANALYSIS 248
16.2.4 PRODUCT PORTFOLIO 248
16.2.5 RECENT DEVELOPMENT 248
16.3 MILTENYI BIOTEC 249
16.3.1 COMPANY SNAPSHOT 249
16.3.2 COMPANY SHARE ANALYSIS 249
16.3.3 PRODUCT PORTFOLIO 250
16.3.4 RECENT DEVELOPMENTS 250
16.4 LUMINEX CORPORATION 251
16.4.1 COMPANY SNAPSHOT 251
16.4.2 PRODUCT PORTFOLIO 251
16.4.3 RECENT DEVELOPMENT 251
16.5 HOLOGIC, INC. 252
16.5.1 COMPANY SNAPSHOT 252
16.5.2 REVENUE ANALYSIS 252
16.5.3 COMPANY SHARE ANALYSIS 253
16.5.4 PRODUCT PORTFOLIO 253
16.5.5 RECENT DEVELOPMENTS 253
16.6 AETHLON MEDICAL, INC. (2022) 254
16.6.1 COMPANY SNAPSHOT 254
16.6.2 PRODUCT PORTFOLIO 255
16.6.3 RECENT DEVELOPMENTS 255
16.7 AGILENT TECHNOLOGIES, INC. 256
16.7.1 COMPANY SNAPSHOT 256
16.7.2 REVENUE ANALYSIS 256
16.7.3 PRODUCT PORTFOLIO 257
16.7.4 RECENT DEVELOPMENT 257
16.8 AMSBI0 258
16.8.1 COMPANY SNAPSHOT 258
16.8.2 PRODUCT PORTFOLIO 258
16.8.3 RECENT DEVELOPMENT 258
16.9 AUDUBON BIOSCIENCE. 259
16.9.1 COMPANY SNAPSHOT 259
16.9.2 PRODUCT PORTFOLIO 259
16.9.3 RECENT DEVELOPMENT 259
16.10 BECKMAN COULTER, INC 260
16.10.1 COMPANY SNAPSHOT 260
16.10.2 PRODUCT PORTFOLIO 260
16.10.3 RECENT DEVELOPMENT 260
16.11 BIOVISION INC. (ACQUIRED BY ABCAM PLC) 261
16.11.1 COMPANY SNAPSHOT 261
16.11.2 REVENUE ANALYSIS 261
16.11.3 COMPANY SHARE ANALYSIS 262
16.11.4 PRODUCT PORTFOLIO 262
16.11.5 RECENT DEVELOPMENT 262
16.12 CELL GUIDANCE SYSTEMS LLC 263
16.12.1 COMPANY SNAPSHOT 263
16.12.2 PRODUCT PORTFOLIO 263
16.12.3 RECENT DEVELOPMENTS 263
16.13 CREATIVE BIOARRAY 264
16.13.1 COMPANY SNAPSHOT 264
16.13.2 PRODUCT PORTFOLIO 264
16.13.3 RECENT DEVELOPMENT 264
16.14 CUSABIO TECHNOLOGY LLC 265
16.14.1 COMPANY SNAPSHOT 265
16.14.2 PRODUCT PORTFOLIO 265
16.14.3 RECENT DEVELOPMENTS 265
16.15 FUJIFILM IRVINE SCIENTIFIC (A SUBSIDIARY OF FUJIFILM HOLDINGS CORPORATION 266
16.15.1 COMPANY SNAPSHOT 266
16.15.2 REVENUE ANALYSIS 266
16.15.3 PRODUCT PORTFOLIO 267
16.15.4 RECENT DEVELOPMENT 267
16.16 HBMLS (ACQUIRED BY LONZA) 268
16.16.1 COMPANY SNAPSHOT 268
16.16.2 REVENUE ANALYSIS 268
16.16.3 PRODUCT PORTFOLIO 269
16.16.4 RECENT DEVELOPMENT 269
16.17 HITACHI, LTD. 270
16.17.1 COMPANY SNAPSHOT 270
16.17.2 REVENUE ANALYSIS 270
16.17.3 PRODUCT PORTFOLIO 271
16.17.4 RECENT DEVELOPMENT 271
16.18 INOVIQ 272
16.18.1 COMPANY SNAPSHOT 272
16.18.2 REVENUE ANALYSIS 272
16.18.3 PRODUCT PORTFOLIO 273
16.18.4 RECENT DEVELOPMENT 273
16.19 JSR MICRO NV 274
16.19.1 COMPANY SNAPSHOT 274
16.19.2 PRODUCT PORTFOLIO 274
16.19.3 RECENT DEVELOPMENT 274
16.20 MICROGENTAS 275
16.20.1 COMPANY SNAPSHOT 275
16.20.2 PRODUCT PORTFOLIO 275
16.20.3 RECENT DEVELOPMENTS 275
16.21 NANOSOMIX 276
16.21.1 COMPANY SNAPSHOT 276
16.21.2 PRODUCT PORTFOLIO 276
16.21.3 RECENT DEVELOPMENT 276
16.22 NEXOSOME-ONCOLOGY 277
16.22.1 COMPANY SNAPSHOT 277
16.22.2 PRODUCT PORTFOLIO 277
16.22.3 RECENT DEVELOPMENTS 277
16.23 NORGEN BIOTEK CORP. 278
16.23.1 COMPANY SNAPSHOT 278
16.23.2 PRODUCT PORTFOLIO 278
16.23.3 RECENT DEVELOPMENTS 278
16.24 NOVUS BIOLOGICALS 279
16.24.1 COMPANY SNAPSHOT 279
16.24.2 PRODUCT PORTFOLIO 279
16.24.3 RECENT DEVELOPMENT 280
16.25 PROTEOGENEX 281
16.25.1 COMPANY SNAPSHOT 281
16.25.2 PRODUCT PORTFOLIO 281
16.25.3 RECENT DEVELOPMENT 281

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.